WO2016100349A3 - Composés azahétérocycliques bicycliques utilisés comme antagonistes des récepteurs nmda nr2b - Google Patents

Composés azahétérocycliques bicycliques utilisés comme antagonistes des récepteurs nmda nr2b Download PDF

Info

Publication number
WO2016100349A3
WO2016100349A3 PCT/US2015/065829 US2015065829W WO2016100349A3 WO 2016100349 A3 WO2016100349 A3 WO 2016100349A3 US 2015065829 W US2015065829 W US 2015065829W WO 2016100349 A3 WO2016100349 A3 WO 2016100349A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
nmda receptor
nr2b
formula
azaheterocyclic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/065829
Other languages
English (en)
Other versions
WO2016100349A2 (fr
Inventor
Gideon Shapiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rugen Holdings (cayman) Ltd
Original Assignee
Rugen Holdings (cayman) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rugen Holdings (cayman) Ltd filed Critical Rugen Holdings (cayman) Ltd
Publication of WO2016100349A2 publication Critical patent/WO2016100349A2/fr
Publication of WO2016100349A3 publication Critical patent/WO2016100349A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des entités chimiques de formule (I), dans laquelle R1 et Z sont tels que définis dans la description, utilisées comme antagonistes sélectifs du sous-type NR2B des récepteurs. L'invention concerne également des compositions pharmaceutiques comprenant une entité chimique de formule (I), et des méthodes de traitement de diverses maladies et divers troubles associés à l'antagonisme NR2B, par ex., de maladies et troubles du système nerveux central, tels que la dépression, par l'administration d'une entité chimique de formule I.
PCT/US2015/065829 2014-12-16 2015-12-15 Composés azahétérocycliques bicycliques utilisés comme antagonistes des récepteurs nmda nr2b Ceased WO2016100349A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462092791P 2014-12-16 2014-12-16
US62/092,791 2014-12-16

Publications (2)

Publication Number Publication Date
WO2016100349A2 WO2016100349A2 (fr) 2016-06-23
WO2016100349A3 true WO2016100349A3 (fr) 2016-08-18

Family

ID=56127835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/065829 Ceased WO2016100349A2 (fr) 2014-12-16 2015-12-15 Composés azahétérocycliques bicycliques utilisés comme antagonistes des récepteurs nmda nr2b

Country Status (1)

Country Link
WO (1) WO2016100349A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015317886A1 (en) 2014-09-15 2017-03-09 Rugen Holdings (Cayman) Limited Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
EP3253761A4 (fr) 2015-02-04 2018-06-20 Rugen Holdings (Cayman) Limited Dérivés 3,3-difluoro-pipéridine en tant qu'antagonistes des récepteurs nmda nr2b
BR112017025023B1 (pt) 2015-06-01 2024-01-30 Rugen Holdings (Cayman) Limited Compostos heterocíclicos de carbamato de 3,3-difluoropiperidina, seu uso como antagonistas do receptor nmda nr2b e composição farmacêutica que os compreende
KR102399848B1 (ko) 2016-10-03 2022-05-19 하이라이트ll 파머슈티컬 (하이난) 컴퍼니, 리미티드 신규한 jak1 선택적 억제제 및 그 용도
WO2018098128A1 (fr) 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Traitement de troubles du spectre autistique, de troubles obsessivo-compulsifs et de troubles de l'anxiété
TW202112378A (zh) 2019-06-04 2021-04-01 德商百靈佳殷格翰國際股份有限公司 嘌呤衍生物及其作為藥物之用途
CN113906033B (zh) 2019-06-04 2024-04-02 勃林格殷格翰国际有限公司 咪唑并吡嗪衍生物及其作为药剂的用途
CN114213424B (zh) * 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3，2-b]并吡啶衍生物的合成方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020165241A1 (en) * 2001-02-23 2002-11-07 Claiborne Christopher F. N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
US20030018038A1 (en) * 1999-10-29 2003-01-23 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US20070149568A1 (en) * 2003-06-04 2007-06-28 Liverton Nigel J N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
US20110172415A1 (en) * 2006-02-23 2011-07-14 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030018038A1 (en) * 1999-10-29 2003-01-23 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US20020165241A1 (en) * 2001-02-23 2002-11-07 Claiborne Christopher F. N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
US20070149568A1 (en) * 2003-06-04 2007-06-28 Liverton Nigel J N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
US20110172415A1 (en) * 2006-02-23 2011-07-14 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group

Also Published As

Publication number Publication date
WO2016100349A2 (fr) 2016-06-23

Similar Documents

Publication Publication Date Title
WO2016100349A3 (fr) Composés azahétérocycliques bicycliques utilisés comme antagonistes des récepteurs nmda nr2b
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2017002775A (es) Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b.
WO2015118342A8 (fr) Composés aza bicycliques en tant qu'agonistes du récepteur muscarinique m1.
NZ737399A (en) Ccr2 modulators
TN2016000263A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
MX379110B (es) Derivados de azaspiro como antagonistas de trpm8.
PH12018500259A1 (en) Muscarinic agonists
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
MX2020010674A (es) Agonistas del receptor muscarinico.
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
EA033497B1 (ru) 1-(тиофенил или фенил)сульфонил-(пирролидин)-2-карбоксамидные производные и их применение в качестве антагонистов trpa1
TN2018000410A1 (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
MX380424B (es) Compuestos heterociclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de n-metil-d-aspartato (nmda) nr2b.
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
WO2014066799A3 (fr) Modulateurs du récepteur des androgènes androgéno-résistant
AR100733A1 (es) Derivados de difluoroetilpiridina como antagonistas del receptor nmda nr2b
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
MX362919B (es) Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1].
WO2018039077A8 (fr) Composés thérapeutiques
MD20160100A2 (ro) Urei asimetrice p-substituite şi utilizările medicale ale acestora
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
PH12016501625A1 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
WO2015111004A3 (fr) Méthode améliorée de préparation de chlorophényl-trifluoroéthanone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15870879

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15870879

Country of ref document: EP

Kind code of ref document: A2